{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:13:01Z","timestamp":1791972781443,"version":"4.3.4"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Data on testosterone replacement therapy and cardiovascular outcomes are conflicting, with the Food and Drug Administration requiring prescription testosterone preparations to indicate a possible increased cardiovascular risk. Whether patients on testosterone replacement therapy undergoing cardiac surgery have an increased risk of postoperative in-hospital mortality and cardiovascular events remains unknown. We therefore sought to identify the impact of testosterone replacement on the incidence of a composite of postoperative in-hospital mortality and cardiovascular events in men undergoing cardiac surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>After institutional review board approval, data from male American Society of Anesthesiologists III\/IV patients \u226540 years of age who underwent cardiac surgery between May 2005 and March 2017 at the Cleveland Clinic (Cleveland, OH) main campus were included. The primary exposure was preoperative testosterone use. The primary outcome was a collapsed composite of postoperative in-hospital mortality and cardiovascular events, including myocardial infarction, stroke, and pulmonary embolism. The secondary outcome was a collapsed composite of minor cardiovascular events, including postoperative rhythm disturbance requiring permanent device, atrial fibrillation, and deep venous thrombosis. We compared patients who received testosterone and those who did not, using propensity score matching within surgical procedure matches. Moreover, as a sensitivity analysis, we used a multivariable logistic regression model to assess the association between testosterone replacement therapy and major or minor cardiovascular events adjusted for potential baseline and intraoperative confounders by including all eligible patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Among 20,604 patients who met inclusion and exclusion criteria, 301 patients who used testosterone routinely within 1 month before the surgery were matched to 1505 of 20,303 patients who did not use testosterone. Among the matched cohort, 8 (2.7%) patients in the testosterone group and 45 (3.0%) in the nontestosterone group had \u22651 major cardiovascular adverse event after surgery. The adjusted odds ratio was 0.89 (95% CI, 0.41\u20131.90;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .756), comparing testosterone to nontestosterone patients. As for the secondary outcomes, 89 (30%) patients in the testosterone group and 525 (35%) patients in the nontestosterone group had \u22651 minor cardiovascular event. The odds of minor events were not significantly different, with an odds ratio of 0.78 (95% CI, 0.60\u20131.02;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .074) comparing testosterone to nontestosterone patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Preoperative testosterone is not associated with a statistically significant increased incidence of a composite of postoperative in-hospital mortality and cardiovascular events after cardiac surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000004115","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T17:29:05Z","timestamp":1553534945000},"page":"890-898","source":"Crossref","is-referenced-by-count":12,"title":["Association of Testosterone Replacement Therapy and the Incidence of a Composite of Postoperative In-Hospital Mortality and Cardiovascular Events in Men Undergoing Cardiac Surgery"],"prefix":"10.1213","volume":"130","author":[{"given":"Maged Y.","family":"Argalious","sequence":"first","affiliation":[{"name":"Department of General Anesthesiology and the Center for Anesthesiology Education, Anesthesiology Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Steib","sequence":"additional","affiliation":[{"name":"Center for Anesthesiology Education, Anesthesiology Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"Daskalakis","sequence":"additional","affiliation":[{"name":"Center for Anesthesiology Education, Anesthesiology Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangmei","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Armanyous","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Glickman Urological and Kidney Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Roselli","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230721","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.amjcard.2015.11.063","article-title":"Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system.","volume":"117","author":"Anderson","year":"2016","journal-title":"Am J Cardiol"},{"key":"R2-20230721","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jamainternmed.2013.6895","article-title":"Trends in androgen prescribing in the United States, 2001 to 2011.","volume":"173","author":"Baillargeon","year":"2013","journal-title":"JAMA Intern Med"},{"key":"R3-20230721","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/jcem.86.2.7219","article-title":"Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.","volume":"86","author":"Harman","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-20230721","doi-asserted-by":"crossref","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men.","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS One"},{"key":"R5-20230721","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration.","volume":"363","author":"Basaria","year":"2010","journal-title":"N Engl J Med"},{"key":"R6-20230721","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2013.280386","article-title":"Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.","volume":"310","author":"Vigen","year":"2013","journal-title":"JAMA"},{"key":"R7-20230721","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1741-7015-11-108","article-title":"Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.","volume":"11","author":"Xu","year":"2013","journal-title":"BMC Med"},{"key":"R8-20230721","first-page":"759","article-title":"Re: Testosterone products: drug safety communication - FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke.","volume":"194","author":"Seftel","year":"2015","journal-title":"J Urol"},{"key":"R9-20230721","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/1060028014539918","article-title":"Risk of myocardial infarction in older men receiving testosterone therapy.","volume":"48","author":"Baillargeon","year":"2014","journal-title":"Ann Pharmacother"},{"key":"R10-20230721","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/jc.2011-2591","article-title":"Testosterone treatment and mortality in men with low testosterone levels.","volume":"97","author":"Shores","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20230721","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1210\/jc.2009-1251","article-title":"Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study.","volume":"95","author":"Srinivas-Shankar","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-20230721","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1517\/14740338.2014.950653","article-title":"Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis.","volume":"13","author":"Corona","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"R13-20230721","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1210\/jc.2009-2575","article-title":"Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis.","volume":"95","author":"Fern\u00e1ndez-Balsells","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20230721","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamainternmed.2016.9546","article-title":"Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency.","volume":"177","author":"Cheetham","year":"2017","journal-title":"JAMA Intern Med"},{"key":"R15-20230721","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00000542-200207000-00030","article-title":"The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist.","volume":"97","author":"Laffey","year":"2002","journal-title":"Anesthesiology"},{"key":"R16-20230721","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1010-7940(01)01099-5","article-title":"Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update.","volume":"21","author":"Paparella","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"key":"R17-20230721","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2164\/jandrol.111.016295","article-title":"Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.","volume":"33","author":"Pastuszak","year":"2012","journal-title":"J Androl"},{"key":"R18-20230721","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1056\/NEJMra022251","article-title":"Risks of testosterone-replacement therapy and recommendations for monitoring.","volume":"350","author":"Rhoden","year":"2004","journal-title":"N Engl J Med"},{"key":"R19-20230721","first-page":"4500","article-title":"Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.","volume":"85","author":"Swerdloff","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20230721","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/ALN.0000000000001757","article-title":"Association of testosterone replacement therapy and the incidence of a composite of postoperative in-hospital mortality and cardiovascular events in men undergoing noncardiac surgery.","volume":"127","author":"Argalious","year":"2017","journal-title":"Anesthesiology"},{"key":"R21-20230721","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-13-0321","article-title":"Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes.","volume":"169","author":"Muraleedharan","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"R22-20230721","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/eurheartj\/ehv346","article-title":"Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men.","volume":"36","author":"Sharma","year":"2015","journal-title":"Eur Heart J"},{"key":"R23-20230721","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1210\/jc.2014-3934","article-title":"Endogenous testosterone and its relationship to preclinical and clinical measures of cardiovascular disease in the atherosclerosis risk in communities study.","volume":"100","author":"Srinath","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-20230721","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.atherosclerosis.2009.10.037","article-title":"Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors.","volume":"210","author":"Akishita","year":"2010","journal-title":"Atherosclerosis"},{"key":"R25-20230721","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1210\/jc.2011-1137","article-title":"Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis.","volume":"96","author":"Araujo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-20230721","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1210\/jc.2013-3272","article-title":"In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality.","volume":"99","author":"Yeap","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-20230721","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.","volume":"95","author":"Bhasin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-20230721","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.mayocp.2014.10.011","article-title":"Testosterone therapy and cardiovascular risk: advances and controversies.","volume":"90","author":"Morgentaler","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"R29-20230721","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1161\/01.CIR.91.11.2742","article-title":"Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses.","volume":"91","author":"Ajayi","year":"1995","journal-title":"Circulation"},{"key":"R30-20230721","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/01.CIR.99.17.2317","article-title":"Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1.","volume":"99","author":"McCrohon","year":"1999","journal-title":"Circulation"},{"key":"R31-20230721","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera.","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"R32-20230721","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1210\/jc.2008-2416","article-title":"Lower testosterone levels predict incident stroke and transient ischemic attack in older men.","volume":"94","author":"Yeap","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-20230721","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease.","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"R34-20230721","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(11)60964-6","article-title":"Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials.","volume":"82","author":"Haddad","year":"2007","journal-title":"Mayo Clin Proc"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000004115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:32:46Z","timestamp":1786113166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000004115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000004115","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}